Bionical Emas is a global Contract Research Organization (CRO) combining Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) bringing life-changing medicines to patients around the world. Their unique integrated business model, with its range of services and capabilities, benefit many of the world’s leading pharma and biotech companies. This distinctive offering enables them to maximize access and generate evidence at every stage of the drug development pathway.
Early Access Programs (often called Expanded Access, Pre-approval Access, Compassionate Use, Named Patient or Managed Access Programs) deliver potentially life-saving treatments to patients around the world while adding true value to clients through a range of additional cutting-edge services.
Bionical Emas are the only specialist Early Access Program (EAP) partner to harness the full power of an established and successful Contract Research Organization. Their global EAP experience in oncology and rare disease areas is perfectly complemented by a range of in-house services.